Pink Sheet is part of the Informa Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

NME Mid-Year Report: Approvals Might Near Record With Strong 2nd Half

Executive Summary

CDER approved 23 new drugs in the first half of 2017, topping the 22 approved in all 2016; there are at least 18 products in CDER's pipeline with a user fee date this year.

Advertisement

Related Content

US FDA Likely To Shatter Novel Approval Record In 2018
Priority Review Designations In US: Third Quarter Spike Continues In 2017
Keeping Track: Cardio, Antibiotic Approvals Put FDA Over Last Year's Novel Drug Count
US FDA's Record-Breaking Month Of Breakthrough Therapy Designations
Novel Approvals Were Fewer But Faster At US FDA In 2016
Do FDA Submission, Approval Declines Outside Cancer Signal Future Treatment Gaps?
User Fee Extensions Are Key To CDER's First Cycle Review Success

Topics

Related Companies

Advertisement
UsernamePublicRestriction

Register

PS121054

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel